Kymera Therapeutics Inc (KYMR) — Cash Flow Reinvestment Rate

Latest as of December 2023: 3.80x

Kymera Therapeutics Inc (KYMR) has a Cash Flow Reinvestment Rate of 3.80x as of December 2023, reinvesting $30.58 Million (capex $11.62 Million plus investments $18.95 Million) from operating cash flow of $8.04 Million. See Kymera Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

3.80x
(Capex + Investments) / Operating CF

Total Reinvested

$30.58 Million
Capex + Investments

Operating Cash Flow

$8.04 Million
USD

Capital Expenditures

$11.62 Million
USD

Kymera Therapeutics Inc Cash Flow Reinvestment Rate (2019–2020)

Historical reinvestment intensity for Kymera Therapeutics Inc across 2 annual periods. For the full cash flow conversion analysis, see how efficiently does Kymera Therapeutics Inc generate cash.

Annual Cash Flow Reinvestment Rate for Kymera Therapeutics Inc (2019–2020)

Year-by-year capital reinvestment analysis for Kymera Therapeutics Inc. See financial agility of Kymera Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2020 4.90x $431.68 Million $88.13 Million $9.10 Million ▲ +432.0%
2019 0.92x $16.49 Million $17.91 Million $532.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow